ORLANDO, FL–(Marketwired – Dec 12, 2016) – Immune Therapeutics, Inc. (OTCQB: IMUN) (“Immune Therapeutics”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer, today announced with immense sadness the passing of Christopher Pearce, one of the founders of Immune Therapeutics and its chief operating officer. Mr. Pearce passed away after a 10-year battle with cancer.
“This is a very sad time for all of us at Immune Therapeutics,” said Noreen Griffin, chief executive officer. “Chris was a great friend, respected colleague and a valuable member of our executive management team. We will miss him deeply. We extend our sympathies to his family and friends at this difficult time.”
About Immune Therapeutics:
Immune Therapeutics is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapies with a focus of providing such therapies in emerging nations. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory and autoimmune diseases.
Immune Therapeutics’ proprietary technology, therapies and patents include the treatment of a wide range of cancers. Its most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone product (LDN) or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Amato and Partners, LLC
Investors Relations Counsel
90 Park Avenue. 17th Floor
New York, NY 10016